title: The transcriptional inhibitors, actinomycin D and alpha-amanitin, activate the HIV-1 promoter and favor phosphorylation of the RNA polymerase II C-terminal domain.
abstract: Actinomycin D and alpha-amanitin are commonly used to inhibit transcription. Unexpectedly, however, the transcription of the human immunodeficiency virus (HIV-1) long terminal repeats (LTR) is shown to be activated at the level of elongation, in human and murine cells exposed to these drugs, whereas the Rous sarcoma virus LTR, the human cytomegalovirus immediate early gene (CMV), and the HSP70 promoters are repressed. Activation of the HIV LTR is independent of the NFkappaB and TAR sequences and coincides with an enhanced average phosphorylation of the C-terminal domain (CTD) from the largest subunit of RNA polymerase II. Both the HIV-1 LTR activation and the bulk CTD phosphorylation enhancement are prevented by several CTD kinase inhibitors, including 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole. The efficacies of the various compounds to block CTD phosphorylation and transcription in vivo correlate with their capacities to inhibit the CDK9/PITALRE kinase in vitro. Hence, the positive transcription elongation factor, P-TEFb, is likely to contribute to the average CTD phosphorylation in vivo and to the activation of the HIV-1 LTR induced by actinomycin D.
authors.affiliation: Laboratoire de Génétique Moléculaire, Ecole Normale Supérieure, 46 rue d'Ulm, 75230 Paris Cedex 05, France.
authors.forename: C
authors.initials: C
authors.lastname: Cassé
authors.forename: F
authors.initials: F
authors.lastname: Giannoni
authors.forename: V T
authors.initials: VT
authors.lastname: Nguyen
authors.forename: M F
authors.initials: MF
authors.lastname: Dubois
authors.forename: O
authors.initials: O
authors.lastname: Bensaude
mesh_terms: D000546:Amanitins / Q000494:pharmacology*; D000818:Animals; D001483:Base Sequence; D001665:Binding Sites; D002460:Cell Line; D042863:Cyclin-Dependent Kinase 9; D018844:Cyclin-Dependent Kinases / Q000378:metabolism; D003587:Cytomegalovirus / Q000235:genetics; D003609:Dactinomycin / Q000494:pharmacology*; D005786:Gene Expression Regulation; D017781:Genes, Immediate-Early; D017930:Genes, Reporter; D016325:HIV Long Terminal Repeat; D015497:HIV-1 / Q000235:genetics*; D018840:HSP70 Heat-Shock Proteins / Q000235:genetics; D006367:HeLa Cells; D006801:Humans; D051379:Mice; D008969:Molecular Sequence Data; D010766:Phosphorylation; D011401:Promoter Regions, Genetic; D012319:RNA Polymerase II / Q000378:metabolism*; D012265:Ribonucleotides / Q000378:metabolism; D014158:Transcription, Genetic / Q000187:drug effects*
chemical_list: D000546:Amanitins; D018840:HSP70 Heat-Shock Proteins; D012265:Ribonucleotides; D003609:Dactinomycin; C026523:5,6-dichloro-1-ribofuranosylbenzimidazole 5'-monophosphate; C467969:CDK9 protein, human; C467972:Cdk9 protein, mouse; D042863:Cyclin-Dependent Kinase 9; D018844:Cyclin-Dependent Kinases; D012319:RNA Polymerase II